Thomas James Doyle, SVP, Finance & Accounting at Kura Oncology, Inc. (KURA), sold 9,832 shares at $8.46 ($83K) on 2026-01-27, disclosed to the SEC on 2026-01-27.
Seasonal sale ($83k) by SVP, Finance & Accounting — this insider has traded KURA in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.46 | 695 | $6K | 7.1% |
| 2 | $8.46 | 881 | $7K | 9.0% |
| 3 | $8.46 | 1,114 | $9K | 11.3% |
| 4 | $8.46 | 2,226 | $19K | 22.6% |
| 5 | $8.46 | 2,226 | $19K | 22.6% |
| 6 | $8.46 | 695 |
| $6K |
| 7.1% |
| 7 | $8.46 | 1,114 | $9K | 11.3% |
| 8 | $8.46 | 881 | $7K | 9.0% |
| Total | $8.46 avg | 9,832 | $83K | 100% |
| Filing → |
| KURA | SELL | 2025-09-29 | $41K | — | Filing → |
| KURA | SELL | 2025-01-28 | $39K | — | Filing → |
| KURA | SELL | 2024-01-31 | $41K | — | Filing → |